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Abstract
A wide deployment of malaria control tools have significantly reduced malaria
morbidity and mortality across Africa. However, in the last five to seven years,
there has been a resurgence of malaria in several African countries, raising the
questions of whether and why current control mechanisms are failing. Since the
first Plasmodium falciparum reference genome was published in 2002, few thou-
sands more representing a broad range of geographical isolates have been
sequenced. These advances in parasite genomics have improved our understanding
of mutational changes, molecular structure, and genetic mechanisms associated
with diagnostic testing, antimalarial resistance, and preventive measures such as
vaccine development. In this chapter, we summarize the current progress on: (1)
genomic characteristics of P. falciparum; (2) novel biomarkers and revolutionary
techniques for diagnosing malaria infections; and (3) current vaccine targets and
challenges for developing efficacious and long-lasting malaria vaccines.
Keywords: genomics, Plasmodium falciparum, malaria diagnosis, bioinformatics,
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1. Introduction
Malaria remains a serious public health problem in several developing countries.
Globally, there are about 3.2 billion people at risk of malaria and 435,000 malaria-
related deaths, most of which happening in West Africa [1, 2]. Malaria is a compli-
cated disease caused by the genus Plasmodium in the protozoan phylum
Apicomplexa. While P. falciparum is the most prevalent form of malaria, P. vivax is
most widespread around the world. Plasmodium has a complicated life cycle that
reproduces asexually in human and sexually in mosquito hosts. The parasite is
transmitted by the female Anopheles mosquitoes. Anopheles mosquitoes thrive in
warm, tropical climates as the temperature allows for quicker breeding and hatch-
ing [3]. The abundance of vectors is positively correlated with the transmission rate
of malaria [4]. People infected with malaria normally experience fever, chills,
diarrhea, vomiting, and anemia [5]. If remain untreated, the disease can progress to
a severe form and result in death [6].
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A wide deployment of malaria control tools in the past few decades have signif-
icantly reduced malaria morbidity and mortality worldwide. The number of coun-
tries with fewer than 100 clinical malaria cases increased from six to 27. Countries
including Iran, Malaysia, Timor-Leste Belize, Cabo Verde, China, and El Salvador
reported zero malaria cases in 2019 and malaria cases dropped by 90% in the
Greater Mekong subregion (GMS) [7]. However, in the last five to seven years,
there has been a resurgence of malaria in several African countries, raising the
questions of whether and why current control mechanisms are failing. A number of
factors has limited malaria control and elimination efforts. First, Plasmodium iso-
lates may respond differently to antimalarial drugs, with some evolved to become
more resistant than the others due to prolonged drug use. Second, multiplicity of
infection (MOI), i.e., the number of Plasmodium isolates co-infecting a single host,
has made molecular characterization of the parasites and understanding of disease
severity difficult [8]. Third, diagnostic inaccuracy related to false negative results
by rapid diagnostic tests (RDTs) is becoming a more widespread phenomenon [9].
Other factors such as asymptomatic reservoirs leading to transmission, lack of
effective vaccine, and warmer climates and changing environments caused by
human activities [10] have also hampered malaria elimination efforts. Thus, it is
critically important to create new tools that allow us to monitor parasite changes
and use that information to improve existing control strategies. In this chapter, we
will summarize the current progress on: (1) genomic characteristics of P.
falciparum; (2) novel biomarkers and revolutionary techniques for diagnosing
malaria infections; and (3) current vaccine targets and challenges for developing
efficacious and long-lasting malaria vaccines.
2. Genomic characteristics of Plasmodium falciparum
Knowledge of the evolution and genetic variation of the Plasmodium genome
offers incredible insights into novel means of malaria diagnosis and treatment. The
advances in parasite genomics have improved our understanding of mutational
changes, molecular structure, and genetic mechanisms associated with failure in
diagnostic testing [11], antimalarial resistance [12], and preventive measures such
as vaccine development [13]. Since the first reference genome of P. falciparum was
published in 2002 [14], several thousand DNA sequences have been collected and
deposited in public databases. Plasmodium falciparum genome is approximately
23.7 Mb with 14 chromosomes, a plasmid of about 35 kb, and lots of mitochondrial
DNA copies of about 6 kb [15]. There are currently 5,438 genes that have been
predicted/discovered within the genome with 33% uncertainty of their functions
[16]. The genome contains many rich AT regions in both exons and introns (80%
and 90%, respectively), which has some advantages and disadvantages when learn-
ing more about the genetic architecture of the parasites [17]. The advantage associ-
ated with the genomic data would be using its rich polymorphic AT content as
biomarkers to map out the evolutionary structure of the parasites and correlating it
with any drug resistant genes [15]. Although having a rich AT genome has contrib-
uted to a high yield in microsatellites or simple sequence repeats, there are some
disadvantages when using the genome in genetic studies [15]. For example, within
CRISPR-Cas9, the high AT content resulted in a decrease in the amount of gRNA
target sites needed [18]. A deeper knowledge of the genome’s polymorphic and
conserved genes are therefore essential towards understanding the evolutionary
timeline of various P. falciparum lineages.
Compared to other eukaryotic organisms, whole genome sequencing (WGS)
showed that the genome of P. falciparum contains fewer genes for enzymes and
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transporters, but more genes for immune evasion to support host–parasite interac-
tions [14]. With an average length of 2.4 Kb, P. falciparum genes are considerably
larger than many organisms. P. falciparum’s genome contains a full set of transfer
RNA (tRNA) ligase genes with minimal redundancy. 43 tRNAs have been identified
to bind all codons except TGT and TGC, which code for cysteine, thus giving P.
falciparum a slightly different amino acid translation than is seen in humans and
other eukaryotes. By contrast, the mitochondrial genome of P. falciparum is only
about 6Kb and does not contain any genes that encode for tRNAs, implying that the
mitochondrion must import tRNAs from elsewhere into the cells [19, 20]. Poly-
morphic genes in the P. falciparum genome are useful in creating linkage maps to
monitor mutational changes and genetic diversity of the parasites in response to
malaria interventions and control efforts [21]. Polymorphic genes are variations in
genes at higher frequencies that can be advantageous, neutral, or disadvantageous
[22]. The role of polymorphic genes is to influence coding regions, alter protein
sequences and gene expression, and eventually the metabolic pathway and function
[23]. For example, remarkable polymorphisms observed in the merozoite surface
proteins (MSP), PfAMA1, PfEBA, and PfRHs genes that involved in merozoite
evasion have been shown to increase the evasion ability of P. falciparum to the host
immune system [24].
In comparison, conserved genes are genes that have not been altered. They
contribute to important biological processes and fitness [25]. Information of con-
served genes allow us to infer phylogenetic relatedness and trace the genetic origin
of different lineages, determine new targets for therapeutic treatment, and serve as
a guide when determining functions of unknown genes [18]. The processes that
determine the polymorphisms of the parasitic genome include both selective pres-
sures and recombination frequencies. Selective pressures on conserved genes allow
certain important genes to remain unmodified for normal metabolic activities,
whereas polymorphic genes diversify through frequent recombination allow for
better evasion of antimalarial drug treatments and escape detection from diagnostic
tests [26]. For example, the PfHRP2 gene has shown with partial deletions and/or
mutations over the past few years due to the usage of HRP2-specific Rapid Diag-
nostic tests (RDTs) [27, 28]. More specifically, the histidine-rich repeats in the
PfHRP2 gene drastically change the length of the gene and the ability of the para-
sites to evade RDTs. Therefore, novel genes that encode for parasite specific func-
tion might be potential new targets for malaria diagnosis and/or treatment [14]. It is
important to distinguish metabolic pathways that the parasites use for invasion of
the host cells as well as evasion of the host immune system.
P. falciparum is clearly genetically distinct by geographical regions [29, 30].
Given the complex life cycle of Plasmodium, genomic data coupled with Genome-
Wide Association Studies can offer deep insights into the tangled relationships
among humans, mosquitoes, and the parasites. To date, databases such as
PlasmoDB have integrated sequence information, functional genomics, and anno-
tation of data emerging from the P. falciparum genome sequencing consortium [31].
These databases provide an important platform to retrieve biological meaning from
new ‘omic’ data and enhance diagnosis and treatment of infections caused by this
dreadful malaria pathogen.
3. Conventional and novel methods for malaria diagnosis
One of the challenges to malaria elimination is the burden of submicroscopic
asymptomatic infections that contribute to malaria transmission [7]. The gold stan-
dard for malaria diagnosis is microscopy [32]. Microscopy can differentiate malaria
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species and quantify parasite density, but only has a detection threshold of 10 to 50
parasites μl of blood (approximately 0.001% parasitemia, assuming an erythrocyte
count of 5  106 cells μl) [33]. However, it requires well trained microscopists and
is labor-intensive and time-consuming [32]. Previous studies have reported higher
prevalence of asymptomatic parasitemia (6–7 times higher) using PCR compared to
microscopy [5]. Nested PCR of the 18 s rRNA genes has been commonly used to
detect submicroscopic infections. PCR-based methods are also more sensitive than
microscopy at detecting gametocytes particularly in asymptomatic individuals with
low-density infections [34]. However, recent studies indicated a relatively high
number of misdiagnosed infections [9], possibly due to low parasite density being
less detectable by conventional PCR. The 18 s rRNA gene has a reported detection
thresholds of 0.5–5 parasites μl [35], but parasite density of asymptomatic infections
especially in low transmission settings could be well below this threshold. As a
result, many of these infections remain undetected in the general populations of
several malaria-endemic countries [10, 36, 37] and provide perfect reservoirs for
transmission at any time. Therefore, it is crucial to identify new gene targets or
novel tools that are convenient and affordable for detecting asymptomatic infec-
tions, particularly in countries approaching elimination phase. Below are compari-
sons of various conventional and novel detection methods.
3.1 Rapid diagnostic test (RDT)
Rapid Diagnostic Test (RDT) is a lateral flow immunochromatographic test that
can detect the presence of Plasmodium parasites by using blood from patients. The
blood samples collected from patients must be lysed before the Plasmodium antigens
being stained. RDT will indicate if the patient has malaria or not [38]. This diagnostic
method is useful in rural areas as it is inexpensive and does not require expertise to
perform the test [38]. There are various types of RDTs that can detect different
antigens of Plasmodium parasites including P. falciparum and P. vivax, namely P.
falciparum histidine-rich protein 2 (PfHRP2) and lactate dehydrogenase (PfLDH).
However, recent studies indicated that parasites lacking the pfhrp2/pfhrp3 genes
could result in false-negative PfHRP2-RDT results, and these pfhrp2/pfhrp3 variants
have been spreading in many East and West African countries [39–42]. Reports of
deletion of HRP2 and HRP3 genes was first reported in 2010 within the Peruvian
Amazon [43] and the number of false negative RDTs has substantially increased in
late 2014 [44]. Prevalence of false negative cases related to HRP2 deletions in South
America (with the exception of Peru) is lower than Asia and Sub-Saharan Africa [45].
The highest prevalence (50% pfhrp2 deletions among all positive cases) were
reported in Cambodia, Peru, and Eritrea [46]. Such a high prevalence could be
explained by technical errors, mutations, selection and spread of the pfhrp2 and 3
variants [47] from South America to Africa and Asia [41]. Recently, a novel HRP2-
based Alere™Malaria Ag P.f RDT (uRDT) was developed specifically for the detec-
tion of asymptomatic infections. Compared to the existing RDTs, the uRDT showed a
greater than 10-fold improvement in diagnosing clinical and asymptomatic cases
[48]. However, the sensitivities of the uRDT were inconsistent among different
transmission settings [49]. Thus, although very promising for the detection of
asymptomatic infections, the performance of uRDT must be further evaluated espe-
cially in areas with a already high prevalence of pfhrp2 and pfhrp3 gene deletions.
3.2 Enzyme-linked immunosorbent assay (ELISA)
ELISA is an enzyme-linked immunosorbent assay that is used to detect antigens
and antibodies by utilizing a highly specific antibody–antigen interaction and their
4
Current Topics and Emerging Issues in Malaria Elimination
bonding affinity to proteins on a solid surface [50]. Samples, including and positive
and negative controls are inserted on a 96 well plate which enables the possibility to
analyze multiple samples simultaneously, then samples get incubated and detection
of the signal is generated directly or indirectly via secondary tag on the specific
antibody [51]. ELISA can be very efficient diagnostic tool for Plasmodium because it
is highly specific and sensitive and therefore can be used to screen blood donors and
pregnant women who may or may not have been exposed to the parasite [1].
However there are some limitations associated with using ELISA, as it is unable to
detect antibodies in patients with acute infections, patients with different Plasmo-
dium species, and various antigens within the different life stages of the parasite
[52]. A recent study showed a lower detection threshold (3 parasites/μl) by ELISA
test of the Plasmodium lactate dehydrogenase (pLDH) as compared to RDT (50–60
parasites/μl) [53]. However, ELISA has a lower sensitivity (69.9%) to antigens than
RDT (88%) [53], and can be expensive and require a trained technician to operate
and interpret the results [53].
3.3 Lateral flow immunoassay (LFIA)
One of the current diagnostic tests in development is an antibody-based lateral flow
immunoassay (LFIA). Unlike ELISA that requires repeated incubation and washing
steps, LFIA is considered to be a simple, user-friendly and cost-effective method for
front-line diagnosis [54]. LFIA is versatile enough to detect target genes in sample
matrices including whole blood, saliva, and urine. This method is primarily applied to
detecting gametocytes inmalaria-infected samples. Gametocytes are the sexual form of
the parasite that gets transmitted to the mosquito host. They play a very important role
in malaria transmission, and can contribute to up to 80% [55] of the infectious reser-
voirs. Previous studies have shown that infections with parasitemia as low as 4 game-
tocytes/μl can sustain transmission [56]. LFIA targets Pfs25 in infected blood samples,
which is a glycophosphatidylinositol-linked protein expressed on the surface of P.
falciparum zygotes and ookinetes but only found on female gametocytes in the human
hosts [57]. The detection limit of Pfs25 LFIA is 0.02 gametocytes/μl, much more
sensitive than pfhrp2 RDTwith a detection limit of 50–100 parasites per μL of blood
[35, 58]. Another protein at the surface of the female gametocyte PSSP17, which is
presumably more abundant in saliva samples, was also investigated in Cameroon,
Zambia and Sierra Leone with an estimated sensitivity of 83% (95% CI, 61 to 95) in
symptomatic patients when compared to PCR as the gold standard [58]. Detection of
pfhrp2 in saliva have been reported recently using LFIA, but the sensitivity was only
shown to be improved in severe to moderate form of infections with parasitemia
>60,000 parasites/μL [59]. Although convenient, pfhrp2-based LFIA could be less
useful in detecting asymptomatic infections.
3.4 PCR-based methods
The combination of PCR-based assays and sequencing technologies have revo-
lutionized malaria diagnosis since their introduction in the early 2000s. Various
gene targets have be used to monitor genetic and/or mutational changes in the
parasites that cause the disease. PCR is a very common technique used in malaria
diagnoses in laboratory settings. The main advantage of this technique is that it
enables us to identify individuals with low parasitemia (Table 1). There are multi-
ple versions of this technique including nested conventional PCR, real-time quanti-
tative PCR and reverse transcriptase PCR. Nested PCR is the easiest and least
expensive methods among the others. It only requires a thermocycler, set of
primers, reagents and visualization after gel electrophoresis. It is mostly a
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qualitative method as it is fairly difficult to estimate parasite density on a agarose
gel. Unlike conventional PCR that uses gel electrophoresis to visualize PCR prod-
ucts, real-time PCR or qPCR detects and quantifies the amount of amplified DNA
usually by SYBR green or a fluorogenic probe designed based on a target gene
segment (TaqMan). The standard cycle threshold (Ct) value is inversely propor-
tional to the amount of target DNA in the sample [66] and allows estimation of
parasite density even in submicroscopic samples. Different from nested and qPCRs,
reverse transcriptase PCR uses RNA as template and transcribes RNA into comple-
mentary DNA. This method has been widely used to detect and quantify gameto-
cyte density in malaria samples. Though PCR-based methods are undoubtedly more
sensitive than microscopic diagnosis, the level of sensitivity is highly dependent on
the gene targets (Table 1).
3.4.1 18 s rRNA
The 18 s rRNA genes have been the main gene target for molecular screening as it
contains 5–8 copies per genome [62] in Plasmodium, but recent studies indicated a
relatively high level of misdiagnosed infections [45]. The advantage of using the 18 s
rRNA is that it is highly specific compared to microscopy or RDT diagnoses. The
primer sequences and protocols for both nested and qPCRs have been readily
established. However, it fails to reveal infections with low parasite density (0.5–5
parasites/μL of blood) [35]. Thus, new target genes have been examined in the past
few years with the goal to achieve an ultra-sensitive biomarker with higher sensi-
tivity and specificity compared to the 18 s rRNA.
3.4.2 Mitochondrial cytochrome c oxidase III (COX3)
The cytochrome c oxidase III (COX3) gene plays a very important role in cellular
respiration [67]. It is a mitochondrial gene that inherited solely from the female
gametocyte and less likely to undergo genetic recombination, making it an ideal





Application Detection Limit Refs
RDT HRP2/3 57 99 Field 50–100 parasites/μL of blood [35]
RDT LDH 58 93 Field 50–100 parasites/μL of blood [35]
PCR 18 s rRNA 64 92 Laboratory 0.5–5 parasites/μL of blood [60]
PCR COX3 — — Laboratory 0.6–2 parasites/μL blood [60]
PCR TARE-2 81 49 Laboratory 6–24 parasites in 200 μL
whole blood
[61]
PCR varATS — — Laboratory 12–30 parasites in 200 μL
whole blood
[62]
PCR Pfs25 — — Laboratory 0.3 mature females/μL blood [63]
ELISA LDH 69.9 100 Laboratory 3 parasites/μL blood [53, 64]
LFIA Pfs25 — — Laboratory 0.02 gametocytes/μl blood [58]
SERS Hemozoin — — Laboratory 30 parasites/μL of blood [65]
— Denotes that the sensitivity or specificity is not reported.
Table 1.
Existing malaria diagnostic tests and their respective performance.
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More importantly, there are around 20 to 150 copies of the COX3 gene in the
Plasmodium genome [62] and PCR analysis of this gene indicated a detection limit
of 0.6–2 parasites/μL, much more sensitive than the 18 s-rRNA [60].
3.4.3 Telomere associated repetitive element 2 (TARE-2)
The recently discovered Telomere Associated Repetitive Element 2 (TARE-2) has
demonstrated better performance than the conventional 18 s rRNA marker in
detecting low density parasite infections. There are about 250 copies of the TARE-2
gene in the Plasmodium genome and this gene is highly specific to P. falciparum [69].
TARE-2 has been previously shown to be useful for detecting ultra-low density P.
falciparum infections in Papua New Guinea and Tanzania [62]. A recent study in
Ghana showed a slightly higher sensitivity of TARE-2 compared to 18 s rRNA (81.2%
vs. 80.9%) using microscopy as a gold standard, but with a lower specificity reduced
by almost two-fold [37], making this gene less desirable for active case surveillance.
3.4.4 Var. gene acidic terminal sequence (varATS)
The var gene family is located primarily in the subtelomeric region of the Plasmo-
dium genome. It is a family of genes known to be highly polymorphic. For instance, the
genome of the 3D7 culture strain harbors 59 different var genes with an estimated 50–
150 copies per genome [14]. One of themain gene in the var gene family encodes the P.
falciparum erythrocyte membrane protein 1 (PfEMP1) that contains a highly variable
extracellular part and a well conserved intracellular var gene acidic terminal sequence
(varATS) [61]. The varATS has a detection limit of 12–30 parasites in 200 μL whole
blood. Though more sensitive 18 s rRNA, varATS employs a qPCR approach that could
be less feasible for routine case detection in rural areas or developing countries [62].
3.5 Raman spectroscopy
Raman spectroscopy is a relatively novel technique that can be used to diagnose
the presence of Plasmodium. This technique measures the amount of wavelength
and light intensity of scattered light reflected from the target molecule of Plasmo-
dium present in an infected sample either in liquid, gas, or solid form [70]. Raman
spectroscopy can be used specifically to characterize hemozoin, a pigment produced
by infected erythrocytes and can be used to track the progression of the disease and
efficacy of drug treatment [71]. A specific type of Raman spectroscopy known as
Surface Enhanced Raman Spectroscopy (SERS) has been utilized to detect early
signs of erythrocytic infections and was shown with a detection limit of 30 para-
sites/μL [65]. Tip-enhanced Raman spectroscopy (TERS), on the other hand, can
enhance Plasmodium’s hemozoin vacuole from 106 to 107 [71]. While Raman spec-
troscopy is more cost effectiveness than PCR and microscopy [71], this technique
cannot detect hemozoin in early ring stage nor differentiate hemozoin from active
and previous infections [71]. Further investigations are needed to refine Raman
signals in order to enhance the technique’s detection abilities.
4. Revolutionized techniques and genomics tools for monitoring
parasite changes
Extensive level of genetic diversity observed in Plasmodium is a major threat to the
eradication of the disease. Previous studies used sanger sequencing of the merozoite
surface protein (MSP) or microsatellite genotyping methods to assess parasite genetic
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diversity. Though affordable, these methods are time-consuming and labor-intensive
for large scale genetic studies. Moreover, differentiating or phasing clonal genotypes
for samples with more than two clones can be difficult. Restriction enzyme cutting
followed by gel electorphoresis of the MSP gene has been conventionally used to
assess parasite diversity and define multiplicity of infections (MOI) based on the
number of distinct bands present on a gel. MSP is the most abundant protein at the
surface of the merozoite and play a critical role in the Plasmodium invasion mecha-
nism to the erythrocyte [72]. It is an informative gene for resolving clonal relation-
ships and depicting population structure of Plasmodium given its size polymorphisms
[73]. However, in high transmission areas where parasites are highly variable and
different by single nucleotide polymorphisms (SNPs), gel electorphoresis of the MSP
gene would underestimate the levels of diversity and polyclonality [74]. Microsatel-
lite genotyping has also extensively been used for Plasmodium population structure
and genetic diversity study [75]. While this marker has the advantages of being
polymorphic, evolutionary neutrally, and are abundant in the Plasmodium genome
[76], polyclonal samples with more than two alleles detected from two or more
genetic loci are usually discarded in the analyses. Thus, next-generation sequencing
(NGS) technologies offer a novel, alternative approach to shed light on the polyclonal
and complex nature of Plasmodium infections [77].
4.1 Amplicon deep sequencing
In regions in high malaria endemicity, individuals typically harbor multiple Plas-
modium falciparum isolates due to repeated exposure to mosquitoes infected with
multiple parasite isolates [78]. Polyclonal infections have become a growing concern
as some parasite isolates may be resistant to antimalarial drugs and/or more patho-
genic [79]. Identification of genetically distinct clones is necessary to critically evalu-
ate the causation of resistance to drugs and any other therapeutic treatments.
Recently, due to reduced cost of high throughput NGS technology, other types of
molecular tools have emerged to address the complex issue related to MOI. MOI is
defined as the number of parasite clones within an infected sample. Deep sequencing
of a targeted gene amplicon coupled with bioinformatic analyses allow differentiation
of various P. falciparum strains based on SNPs [75] and discrimination of major from
minor clones [80]. It also provides an increased capability to detect the genetic
relatedness among clones within and between hosts as well as minor P. falciparum
variants [81]. This technique can be applied to different gene regions such as
Circumsporozoite (CSP), MSP1/2, and Apical membrane antigen (AMA) to monitor
changes as well as selection pressure acting on the parasite populations [82].
4.2 Molecular inversion probe
Molecular inversion probes (MIPs) are another deep sequencing technique that
targets several short gene regions across the genome. MIPs are single stranded DNA
molecules that contain flanking regions of the targeted gene regions up to several
hundred base pairs long [83]. MIPs can hybridize with the target sequence and
undergo gap filling ligation to form circular DNA. The target sequence will also
contain adaptors and barcodes to be further amplified by PCR [83]. The advantages
of this technique include low rate of errors, small amount of DNA samples, high
throughput, and cost-effective for several hundreds of samples. It is scalable to the
number of targeted gene regions and samples, requires minimal costs in terms of
reagents and labor, and allows efficient capture of DNA extracted from dried blood
spots [84]. The latter advantage would make large-scale population studies feasible.
MIPs have been used for monitoring SNP mutations associated with drug
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resistance, such as crt, mdr1, dhps, dhfr, and K13 (Table 2) [84]. For example, a
recent study based on MIPs analysis found that the PfDHPS gene associated with
Sulfadoxine resistance has been rapidly spread from east to west of the Democratic
Republic of Congo [84]. Apart from drug-resistant mutations, a number of micro-
satellite loci have also been added to the MIP panel to estimate genetic structure and
diversity of P. falciparum. This technique allows multiple loci to be genotyped
simultaneously. However, the design of the MIP panel would require prior infor-
mation of the gene regions of interest.
5. From parasite genes to malaria vaccines
Genetic information of P. falciparum has allowed a careful selection of gene
targets for vaccine development [85]. Vaccines can offer protection against clinical
malaria especially in young children and reduce transmission in a population. How-
ever, there are several challenges in developing a highly effective malaria vaccine,
mostly due to the complexity in the parasite life cycle and host immune system.
Plasmodium parasites reproduce asexually in human hosts. They can be found
throughout the body’s bloodstream and liver in various stages. There are numerous
potential parasite antigens that elicit different levels of host immune response [86],
but the protective response towards a particular antigen or one parasite life-stage is
not effective in conferring protection against other stages [87]. One solution for that
is to choose an immunogenic antigen/epitope that can elicit a strong immune
response and potentially confer the highest efficacy. Conjugating the target antigen
or epitope with an adjuvant or better drug delivery system can help elicit a stronger
and safer immune response [88]. Alternatively, it is also possible to activate other
immune cells such as natural killer cells and neutrophils that can elicit a long-lasting
immune response [89]. Natural killer cells act faster than T cells while neutrophils
can activate either a humoral or cell mediated immunity [90]. Both natural killer
cells and neutrophils in response to P. falciparum invasion have not been studied in
depth compared to antibodies and T cells [90]. To date, there are three types of
malarial vaccines that are being studied and tested in clinical trials: pre-erythrocytic,
erythrocytic, and transmission blocking vaccines (Table 3).
5.1 Pre-erythrocytic vaccines
Pre-erythrocytic vaccines aim to kill infected hepatocytes and prevent sporozo-
ites from reaching the liver [91]. There are various gene targets currently being
investigated and in clinical trials.
5.1.1 RTS,S/AS01E
RTS,S/AS01E is a well-known pre-erythrocytic vaccine that has successfully
completed phase III of clinical testing. It is currently distributed by World Health
Anti-
malarial
Chloroquine Amodiaquine Sulfadoxine Pyrimethamine Artemisinin
Gene Crt Mdr1 Dhps Dhfr K13







Gene mutations associated with antimalarial drug resistance.
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Organization (WHO) in Malawi, Ghana, and Kenya to further investigate vaccine
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P. falciparum. CSP are surface proteins that is important in hepatocyte invasion.
Interactions between CSP and heparin sulfate proteoglycans (HSPGs) allows the
sporozoite to attach to the surface of hepatocytes and triggers a signaling cascade
that allows for the sporozoite to invade liver cells [93]. Subsequent to invasion, the
sporozoites will mature, multiply, and feed on the hepatocytes until the hepatocytes
lyse and release merozoites into the bloodstream. Preventing the invasion of sporo-
zoites will inhibit the progression and severity of the disease. Using the C-terminus
and central tandem repeat (NANP) of PfCSP, Hepatitis B surface membrane anti-
gen (HSbAg), and an AS01 adjuvant system, the vaccine will elicit a strong, stable
immune response [94]. After vaccination, the host immune system will response to
PfCSP antigen by producing anti-CSP antibodies and activating CD4+ T cells [95].
RTS,S/AS01E is given on a three-dose schedule within three months followed by a
fourth dose at 20 months [94]. It has been shown across clinical malarial studies
that the vaccine has an 39–50% efficacy in children ages 5–17 months and 23–30%
efficacy in children ages 6–12 months [96–98]. Efficacy warned rapidly from 35.2%
and 20.3% to 19.1% and 12.7%, respectively, in children and infants within 20–
32 months without a booster [94]. Such a decay in vaccine efficacy could be due to
reduced IgG and IgM antibodies against CSP antigen. Anti-CSP antibodies were
shown to increase by almost 10-fold from 318.2 EU/mL to 34.2 EU/mL in children
one month after a booster was given [92]. Apart from the short-lived nature of the
vaccine, older children who were vaccinated showed an increased risk of malarial
infections, likely due to RTS,S/AS01E interference with naturally acquired immu-
nity [92]. Another similar vaccine R21 is currently testing in Phase 1/2a clinical trials
[99]. This vaccine aims to elicit a high anti-CSP antibody content similar to the
mechanisms of RTS,S vaccine. R21 comprises particles from CSP-HBsAg protein
infused with an adjuvant, matrix-M [99]. It has been shown to increase the pro-
duction of T cells and is still in the process of development [92]. Further studies
should investigate alternative antigens that can elicit stronger and long-lasting
efficacy as well as the mechanisms of the cell-mediated immune response against
malaria in humans.
5.1.2 PfSPZ
Plasmodium falciparum sporozoites (PfSPZ) is another pre-erythrocytic vaccine
target. As aforementioned, sporozoites transferred from the infected Anopheles
mosquito to the human host. They enter the bloodstream and reach the liver before
invading the hepatocytes using the sporozoite proteins P36 and P52. P36 interacts
with hepatocyte’s extracellular receptor EphA2 to create a protective
parasitophorous vacuole that facilitates hepatocyte invasion [100]. PfSPZ vaccine
prevents the sporozoites reaching the liver and infecting hepatocytes [101], and is
currently undergoing phase III clinical trial [102]. PfSPZ vaccine was designed to
have a live, whole sporozoite that is radiated-attenuated. It is injected intravenously
and given in 3–5 doses. Recent studies using controlled human malaria infection
(CHMI) showed that this vaccine provided about 33 weeks of stabilized protection
in 50% of the vaccinated subjects [103]. The vaccine induced interferon gamma
(IFN-γ) that can recruit and activate CD8+ and CD4+ T cells against homologous
and heterologous parasitic strains [103]. Subjects who received the PfSPZ vaccine
also developed IgM antibodies that can help inhibit proliferation of the parasites
[104]. However, the vaccine requires specific storage in ultra-cold condition and
trained medical workers to inject the vaccine intravenously [92]. Furthermore,
efficacy varied by locations. For example, in Mali, 29% efficacy was reported in
subject who were exposed to heterologous strain; whereas in CHMI, 83% of subjects
were found to be protected from exposure to heterologous strains [102]. Further
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studies are needed to compare efficacy among different geographical or transmis-
sion settings.
5.1.3 PfLSA-1 and PfLSA-3
Liver surface antigen (LSA) is another pre-erythrocytic vaccine target. LSA is
essential for the survival of the parasites during the late liver schizogony stage
[105]. Schizonts are asexual stage of Plasmodium that developed from sporozoites
and matured in infected hepatocytes. Once the infected hepatocytes are filled up
with mature schizonts, they rupture and release merozoites into the bloodstream to
invade erythrocytes. LSA vaccine prevents the maturation of schizonts and rupture
of infected hepatocytes. There are two liver stage antigens, LSA-1 and LSA-3, that
are used as vaccine targets. PfLSA-1 is high conserved in P. falciparum and is found
in parasitophorous vacuole in the liver stage of the parasites. PfLSA-1 contains 17
amino acids repeats and is associated with the late liver schizont stage [105, 106].
LSA-1 can induce IgG and IgM antibodies as well as CD4+ T cell production
[105, 107]. LSA-1 vaccine is currently in phase I clinical trial and is still unclear its
efficacy in humans. LSA-3, on the other hand, is found in dense granules in the
blood stage of the parasites and the protein is about 175 kDa [108]. LSA-3 appears to
play a role in the parasitic growth in infected hepatocytes and erythrocytes [108]. A
recent study indicated that LSA-3 provided full protect to chimpanzees from heter-
ologous P. falciparum sporozoites [105]. Like LSA-1, LSA-3 is also in phase I clinical
trial and its efficacy and immunogenicity in humans remain unclear.
5.2 Erythrocytic vaccines
Erythrocytic vaccines aim to kill and terminate the asexual reproduction and
invasion of the parasite within red blood cells (RBC). Infected individuals typically
experience symptoms when the parasites invade a threshold number of RBCs and
disrupt their normal functions. Preventing the parasites developed into blood stage
will inhibit progression of malaria symptoms such as chills, aches, and fevers.
5.2.1 PfMSP1
Merozoite surface protein 1 (MSP1) is one of the targets used for erythrocytic
vaccine. MSP1 is a glycosylphosphatidylinositol-anchored protein found in abun-
dance on the surface of the merozoites [109]. MSP1 plays an important role in the
invasion of erythrocytes as it binds and recruits other peripheral merozoite surface
proteins to form a complex [109]. MSP1 starts off as a precursor of about 196 kDa
and then cleave into four subunits before invading the erythrocytes [110]. The four
subunits are held non-covalently forming a complex attached to the merozoite’s GPI
anchor [110]. Once the MSP1 complex is formed, it binds with the receptors on
erythrocytes and activates a spectrin-binding function to enter the erythrocytes
[110]. MSP1 has been shown to elicit both humoral (IgM and IgG antibodies) and
cell-mediated immune responses (memory T cells) that lasted about 6 months after
immunization [110]. These results are promising as MSP1 vaccine will also activate
antibodies for complement fixation, induce opsonizing antibodies, and initiate
secretion of reactive oxygen species by other immune cells [110]. To date,
MSP1 vaccine is in phase I clinical trial. Further investigation is needed to evaluate
efficacy.
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5.2.2 PfAMA-1
The erythrocytic vaccine based on Apical Membrane Antigen 1 (AMA1) is cur-
rently in phase II clinical trial [111]. The AMA1 protein is approximately 83 kDa and
can be found in both the merozoite and sporozoite stages of P. falciparum [111]. The
complex AMA1 and another parasite protein namely the rhoptry neck protein 2
(RON2), is essential for merozoite invasion during the blood stage of infection, and
initiates the parasite traversal into the RBCs [112]. The AMA1 vaccine has been
shown to elicit high levels of antibodies that can block the invasion of the erythro-
cytes, despite high polymorphisms observed in the AMA1 protein [112]. The AMA1-
Diversity Covering (DiCo) vaccine was thus designed to include three recombinant
variants of AMA1 and this vaccine is currently testing in phase Ia/Ib clinical trial
[113]. To increase efficacy of the AMA1 vaccine, AMA1 was paired with the RON2
receptor and vaccinated in eight Aotus monkeys [112]. Half of the monkeys were
able to achieve complete immunity from the P. falciparum infection when vacci-
nated with AMA1 and RON2 [112]. The vaccine with AMA1 and RON2 induced a
higher level of antibodies than the AMA1 vaccine. Further investigation is needed to
examine other potential AMA1 variants or merozoite structures that can be paired
up with the AMA1 protein to increase efficacy.
5.2.3 PfGARP
Plasmodium falciparum glutamic acid rich protein (PfGARP) is an 80 kDa anti-
gen commonly expressed on the surface of infected erythrocytes during the late
trophozoite stage [114]. The PfGARP gene is relatively conserved. Antibodies
against the PfGARP antigen protein have been shown to confer protection against
severe malaria and reduce parasite densities by 3.5 folds [115]. Further, anti-
PfGARP antibodies were able to successfully induce apoptosis in ring-stage parasite
cultures, resulting in full loss of their mitochondrial function within a 24 hour
period [115]. In addition, the size of food vacuoles in the parasites was decreased or
condensed tightly around the hemozoin crystals, making them inaccessible and
parasite growth was reduced by 76–87% in vitro [115].
5.2.4 PfRH5-PfCyRPA-PfRipr (RCR) complex
The PfRH5-PfCyRPA-PfRipr (RCR) complex is a protein trimer composed of
three different proteins PfRH5, PfCyRPA, and PfRipr that are found on the surface
of merozoites [116]. P. falciparum Reticulocyte-binding Protein Homolog 5 (PfRH5)
is a 63 kDa protein commonly expressed during the schizont stage. After PfRH5
binds with basigin (a receptor found on human erythrocytes), a large amount of
calcium is released to initiate invasion [116]. Monoclonal antibodies against PfRH5
has been found to disrupt the binding between basigin and PfRH5 [116]. P.
falciparum Cysteine-rich Protective Antigen (PfCyRPA) is a highly conserved
43 kDa protein [116]. It plays an important role in erythrocyte invasion by
interacting with PfRH5 to bind to the receptor basigin [56]. Although PfCyRPA is
not immunogenic compared to PfRipr and PfRH5, monoclonal antibodies produced
against this protein can cause cross strain neutralization [116]. P. falciparum RH5-
interacting Protein (PfRipr) is a highly conserved 120 kDa protein found in the
schizont stage [116]. It is composed of 87 cysteines and 10 epidermal growth factor-
like (EGF) domains [116]. Prior to erythrocyte invasion, PfRipr cleaves into two
different fragments including the N-terminus and C-terminus. The N-terminus
contains EGF domains 1 and 2 while the C-terminus contains EGF domains 3–10
[116]. Antibodies against PfRipr EGF domains 6–8 have been shown to neutralize
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the parasites [116]. Combining the anti-PfCyRPA c12 mAb with anti-RH5 BS1.2
mAbr will inhibit parasite growth in vitro from 21–31% to 59%. Thus, this antigen
protein complex is expected to elicit a strong immune response against blood stage
P. falciparum [117].
5.3 Transmission blocking vaccine (TBV)
TBV aims to prevent and kill the sexual stages of the Plasmodium parasites
before transferring into the mosquito hosts. This vaccine offers protection against
infection and transmission.
5.3.1 Pfs25
Pfs25 is an important glycophosphatidylinositol-linked protein expressed on the
surface of ookinetes. It is found only within the Anopheles host and is approximately
25 kDa with 11 disulfie bonds [118]. The parasites require Pfs25 to survive in the
Anopheles’s midgut and develop into oocysts [119]. Pfs25 is a conserve protein with
low diversity. Pfs25 vaccine was designed to elicit antibodies against the Pfs25
antigen in humans and prohibit the development and transmission of gametocytes
[120]. However, a recent study based on an adjuvant of Pfs25 and a non-enveloped
virus like protein (VLP) indicated weak IgG antibody responses in healthy individ-
uals [121]. In another study, the antibody response of Pfs25 proteins combined with
four different adjuvants including alum, Toll-like receptor 4 (TLR-4) agonist
glucopyranosal lipid A (GLA) plus alum, squalene–oil-in-water emulsion, and GLA
plus squalene–oil-in-water emulsion were compared in mice. Pfs25 combined with
GLA plus squalene–oil-in-water emulsion was shown to induce the highest amounts
of IgG antibodies [122]. Further studies should examine the formulation of this
vaccine for better efficacy.
5.3.2 Pfs230 and Pfs48/45
Pfs230 and Pfs48/45-based vaccines are antigens rich in cysteine produced by the
sexual stage gametocytes [123]. Pfs48/45 can be found on the plasma membrane
surface of both male and female gametocytes and are bounded to a GPI anchor that
form a complex with Pfs230 [124]. Pfs230 is a 230 kDa protein that contains 14 6-
cysteine rich domains [123]. Pfs48/45, on the other hand, contains three 6-cysteine
rich domains [124]. The 6-cysteine rich domains of these antigens are essential for
the formation of disulfide bonds on epitopes needed for antibody elicitation [124].
A recent study showed that mice injected with fragments of Pfs48/45 and Pfs230
prodomain produced higher levels of antibodies that induced complement fixation
[124]. Pfs230 and Pfs48/45 combined with a FAB fragment of a monoclonal anti-
body 4F12 have been shown to further increase vaccine efficacy [123]. This vaccine
is currently in early clinical development phase [123, 124].
6. Conclusion
WHO aims to achieve malaria elimination in at least 35 countries, reduce inci-
dence and mortality rates by 90%, and prevent resurgence in malaria-free countries
by 2030. This ambitious goal has been challenged by the emergence and spread of
antimalarial resistance, inaccurate diagnostic testing, asymptomatic transmission,
and lack of effective vaccines [126]. Information of the Plasmodium genomes allow
us to improve and reinvent tools/techniques for monitoring parasite changes as well
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as tracking and stopping transmission of the disease. Several hundreds of
P. falciparum genomes have been generated in the past two decades. Genetic varia-
tion and function of various genes have improved our understanding of mutational
changes, molecular structure, and evolutionary mechanisms in Plasmodium. There
is an urgent need to retrieve utmost biological meaning from the available genomic
data and translate such into tools that help resolve epidemiological challenges. This
includes the identification of novel antigens for accurate and affordable diagnostic
assays and vaccines, informative biomarkers that can distinguish different isolates
and pinpoint the source of infections at fine geographical scale, and sensitive tool(s)
for large-scale screening of asymptomatic infections in both high and low trans-
mission areas. Future studies should examine how climate/environmental changes
and selective pressure from interventions mediate genetic changes in the parasites,
how host immune system responses to parasite changes, and how to uncover hidden
parasite reservoirs and effectively control transmission.
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